End-of-day quote
Shenzhen S.E.
06:00:00 2024-07-16 pm EDT
|
5-day change
|
1st Jan Change
|
19.72
CNY
|
+0.56%
|
|
+0.51%
|
-33.89%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,339
|
10,200
|
9,894
|
13,394
|
8,855
|
-
|
-
|
Enterprise Value (EV)
1 |
6,339
|
10,200
|
9,894
|
13,394
|
8,855
|
8,855
|
8,855
|
P/E ratio
|
28.1
x
|
33.6
x
|
36.2
x
|
71
x
|
24.7
x
|
19.4
x
|
22.8
x
|
Yield
|
-
|
-
|
0.58%
|
0.7%
|
0.51%
|
0.66%
|
-
|
Capitalization / Revenue
|
3.78
x
|
-
|
4.34
x
|
5.35
x
|
3.19
x
|
2.39
x
|
2.41
x
|
EV / Revenue
|
3.78
x
|
-
|
4.34
x
|
5.35
x
|
3.19
x
|
2.39
x
|
2.41
x
|
EV / EBITDA
|
-
|
-
|
26.7
x
|
34.4
x
|
14.5
x
|
12.3
x
|
11.8
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
5.12
x
|
5.37
x
|
3.32
x
|
2.83
x
|
2.78
x
|
Nbr of stocks (in thousands)
|
425,993
|
426,174
|
429,162
|
449,027
|
449,027
|
-
|
-
|
Reference price
2 |
14.88
|
23.93
|
23.05
|
29.83
|
19.72
|
19.72
|
19.72
|
Announcement Date
|
3/29/21
|
4/20/22
|
4/19/23
|
4/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,675
|
-
|
2,280
|
2,503
|
2,777
|
3,705
|
3,674
|
EBITDA
1 |
-
|
-
|
369.9
|
389.8
|
609.8
|
720.8
|
747.4
|
EBIT
1 |
-
|
-
|
282
|
213.9
|
271.5
|
460.6
|
442.6
|
Operating Margin
|
-
|
-
|
12.37%
|
8.55%
|
9.78%
|
12.43%
|
12.05%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
326.4
|
244.2
|
308.3
|
495
|
471.3
|
Net income
1 |
-
|
306.9
|
290.7
|
184.6
|
333.4
|
462.3
|
394
|
Net margin
|
-
|
-
|
12.75%
|
7.37%
|
12.01%
|
12.48%
|
10.72%
|
EPS
2 |
0.5296
|
0.7133
|
0.6373
|
0.4200
|
0.8000
|
1.017
|
0.8667
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.1333
|
0.2100
|
0.1000
|
0.1300
|
-
|
Announcement Date
|
3/29/21
|
4/20/22
|
4/19/23
|
4/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
14.6%
|
8.14%
|
8.77%
|
12.5%
|
11.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
8.07%
|
6.2%
|
8.67%
|
8.1%
|
Assets
1 |
-
|
-
|
-
|
2,287
|
5,378
|
5,334
|
4,864
|
Book Value Per Share
2 |
-
|
-
|
4.500
|
5.550
|
5.940
|
6.980
|
7.100
|
Cash Flow per Share
2 |
-
|
-
|
1.100
|
1.010
|
1.350
|
1.410
|
1.570
|
Capex
1 |
-
|
-
|
606
|
334
|
298
|
230
|
336
|
Capex / Sales
|
-
|
-
|
26.56%
|
13.36%
|
10.73%
|
6.2%
|
9.13%
|
Announcement Date
|
3/29/21
|
4/20/22
|
4/19/23
|
4/26/24
|
-
|
-
|
-
|
Last Close Price
19.72
CNY Average target price
30.72
CNY Spread / Average Target +55.76% Consensus |
1st Jan change
|
Capi.
|
---|
| -33.89% | 1.21B | | +25.40% | 45.35B | | +38.55% | 24.34B | | +27.09% | 16.51B | | +21.19% | 14.6B | | +71.91% | 14.27B | | -0.05% | 6.79B | | -10.10% | 6.57B | | +13.07% | 5.76B | | -8.87% | 5.73B |
Generic Pharmaceuticals
|